Fri, 02nd Apr 2021 00:16
April 1 (Reuters) - British regulators on Thursday said they
have identified 30 cases of rare blood clot events after the use
of the AstraZeneca COVID-19 vaccine, 25 more than the agency
previously reported.
The Medicines and Healthcare products Regulatory Agency said
it had received no such reports of clotting events following use
of the vaccine made by BioNTech SE and Pfizer Inc
.
(Reporting By Peter Henderson and Julie Steenhuysen
Editing by Chris Reese)
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:
(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals In...
(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the Europ...
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommend...
June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worse...
Astrazeneca (AZN)